Team.

Nils is Business Development Lead at Teitur Trophics working on partnerships and fundraising, ensuring progress is communicated to external stakeholders. Combining scientific and business leadership across multiple ventures, Nils has worked across academia and industry for over a decade and has had a particular focus on CNS diseases.

‍

Maya leads ESG initiatives, GDPR compliance & human resources at Teitur Trophics. With an educational and practical background in administration and HR management, Maya supports the focus on sustainability, GDPR compliance and evolvement and optimization of the Teitur operations.

Mia leads Project Management at Teitur Trophics supporting the alignment of the project teams and ensuring good communication between all internal and external parties. With a solid background in academic and biotech research managing preclinical in vivo studies, alongside management of project timelines for key deliverables Mia works to keep progression of our lead assets on track.

Sanne has nearly 20 years of experience in biochemistry and molecular biology techniques and has worked within multiple fields of research including neurodegenerative and metabolic diseases and psychiatric disorders. Sanne oversees operations and maintenance of Teitur laboratories.

Anne Kathrine, PhD in Clinical Medicine, has an extensive background (10years) in glucose and lipid dysregulation at molecular level in metabolic diseases. Her research spans multiple fields where her creative biotechnology engineer intersects with her extensive experience in bridging basic scientific and clinical research. Anne Kathrine explores the therapeutic potential of SorCS-derived peptides for treatment of degenerative disorders.

Emil, PhD in Molecular Medicine, has a rich background in neuroscience(10 years), including extensive experience in cellular and molecular research with in neurodegenerative diseases and in particular Parkinson’s Disease. Emil explores the therapeutic potential of SorCS-derived peptides for treatment of degenerative disorders.

Mathias Kaas Ollendorff, MD, has 10+ years’ experience in neuroscience with particular focus on behavioural phenotyping of sortilin receptor transgenic models. He has guided the testing of Teitur peptides in animal models of neurodegeneration and the assessment of pharmacokinetic properties. Mathias tracks and manages soft-funding opportunities for Teitur programs.